Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients.
Michael PraktiknjoNatalie DjayadiRaphael MohrRobert SchierwagenJenny BischoffLeona DoldAlessandra PohlmannCarolynne Schwarze-ZanderJan-Christian WasmuthChristoph BoeseckeJürgen K RockstrohJonel TrebickaPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
This study presents FGF-21 as an independent and stronger predictor of severe hepatic steatosis than blood lipids in HIV-infected patients. Moreover, arterial hypertension and ALT levels predict severe steatosis even in non-obese HIV-monoinfected patients. Furthermore, this study supports existing metabolic risk factors and expands them to non-obese HIV-infected patients.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- adipose tissue
- hiv aids
- weight loss
- risk factors
- metabolic syndrome
- end stage renal disease
- type diabetes
- early onset
- arterial hypertension
- chronic kidney disease
- ejection fraction
- bariatric surgery
- obese patients
- peritoneal dialysis
- insulin resistance
- high fat diet
- drug induced
- skeletal muscle
- patient reported outcomes
- fatty acid